Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran from Arrowhead for $250 Million and…
Royalty Pharma plc and Arrowhead announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (Nasdaq: ARWR) for $250 million in…
Read More...
Read More...
